We herein report the case of a patient with human immunodeficiency virus infection and acquired immune deficiency syndrome who was diagnosed with drug-induced pure red cell aplasia consequent to lamivudine treatment. The patient was admitted to our hospital for treatment of increasing shortness of breath following physical effort. Upon admission, routine blood tests revealed a hemoglobin level of 7.6 g/dL and a hematocrit proportion of 21.2%, with normal leukocyte and platelet counts. After stopping the lamivudine treatment, the patient's hemoglobin concentration and hematocrit level returned to normal. A bone marrow examination showed an exclusive reduction in erythrocyte formation. This case indicates that lamivudine can induce severe anemia without the influence of zidovudine.
Introduction
Antiretroviral therapy (ART) regimens including the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC) are considered first-line therapy for human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections according to the current treatment guidelines (1) . Furthermore, 3TC is known to delay viral resistance to zidovudine (ZDV) and enhance the effects of ZDV in patients previously treated with ZDV (2) . However, anemia has been reported in 3TC-treated patients who have received either concomitant or previous ZDV treatment (3) (4) (5) . A case of 3 TC-induced pure red cell aplasia (PRCA) was recently reported in an HIV-infected patient with an acute bacterial infection who had not been previously treated with ZDV (6) . To the best of our knowledge, few reports are available regarding this rare side effect of 3TC in the absence of ZDV treatment and presence of simultaneous infection other than HIV. In addition, it remains unclear whether 3TC causes damage solely to the erythrocyte formation system or all bone marrow hematopoietic cells, as a reported case of 3 TC-induced anemia involved myelosuppression in all hematopoietic systems (6) . In this report, we describe a case of 3 TC-induced PRCA in a young HIV patient who received ART without a concurrent or previous history of ZDV treatment. In this case, PRCA manifested as severe normocytic anemia and resolved after the discontinuation of 3TC.
Figure. Bone marrow histology on admission.
A marked reduction in the erythrocyte formation system was observed. Erythroid cells in the bone marrow=12.6%; myelocyte/erythrocyte ratio=5.22 (normal range: 1.5-3.3). ies/mL and his CD4 + T cell count was 320 cells/μL. ART was initiated at a once-daily oral dose consisting of 3TC (300 mg), EFV (600 mg) and ABC (600 mg). This therapy was well tolerated, with the exception of light vertigo, which persisted for several weeks after the initiation of EFV. The patient's medical history included two episodes of duodenal ulcer bleeding due to excessive alcohol consumption; he had discontinued this habit one year prior to admission. For four years, he had regularly self-administered subcutaneous insulin injections to treat type 1 diabetes mellitus. Neither HBV nor hepatitis C virus (HCV) infection was detected. Upon admission, the patient's vital signs showed normal systolic and diastolic blood pressure levels (126/90 mmHg) and sinus tachycardia (113/minutes). Both his conjunctival and oral mucosa were pale, although he had neither hemosputum nor blood in the stool, according to a digital examination. He also exhibited no jaundice, palpable lymphadenopathy or skin rashes. The results of pulmonary and cardiology examinations were normal. Routine hematology, blood chemistry and urine analyses were performed on admission. The hematology tests revealed normocytic anemia with a hemoglobin (Hb) concentration of 7.6 g/dL and a hematocrit (Hct) level of 21.2%, whereas the reticulocyte count was normal. We performed a 400-mL red blood cell transfusion on the day of admission because the reductions in the Hb and Hct levels were severe (Table) . The white blood cell and platelet counts were within the normal ranges. The serum levels of acute-phase inflammation markers were not elevated, and there were no rapid increases in the HIV load (680 copies/mL) or remarkable changes in the CD4/CD8 ratio (0.77) or number of CD4 + T cells (729 cells/μL). Blood chemistry tests demonstrated a normal serum iron level. The vitamin B12 and folate levels were normal, and a direct Coombs test (polyspecific) result was negative. Urine microscopy yielded a normal erythrocyte count. Both aerobic and anaerobic blood and urine cultures were negative, as were serological tests for hepatitis A, HBV and HCV. No signs of opportunistic infections, including mycobacterial infections, were noted. In addition, immunoglobulin levels suggestive of an acute viral infection, such as parvovirus B19 or cytomegalovirus, were not elevated, and there were no increases in the indirect bilirubin or haptoglobin levels. After the patient was admitted, we initially performed a gastrointestinal scope examination due to his previous history of duodenal ulcers. However, we found no signs of intestinal bleeding. His bone marrow specimen showed a marked and exclusive decrease in the erythrocyte formation system (Figure) ; however, there was no evidence of malignant infiltrates, granulomas or giant pronormoblasts-a reported pathognomonic sign of parvovirus B19-associated red cell aplasia (7) (8) (9) . We then suspected a diagnosis of drug-induced anemia and replaced 3TC with stavudine (d4T). Seven days later, the patient's blood Hb concentration and Hct level recovered to 10.3 g/dL and 31.8%, respectively (Table) . A second red blood cell transfusion was not required because the Hct and Hb levels did not decrease after 3TC discontinuation. The patient was discharged three weeks later, and we observed no recurrence of anemia during a one-year follow-up period in the outpatient clinic.
Discussion
Post-ART anemia has been reported to occur at a rate of 9.6/100 person-years and within the first two years of initial treatment regimens (8, 9) comprising the commonly prescribed combination of 3TC and ZDV (10) . Additionally, 13 HIV-infected patients have been reported to have developed severe anemia in association with antiretroviral therapies including 3TC and ZDV (3) . Furthermore, a case of severe anemia has recently been documented during the administration of 3TC-and ZDV-containing therapy (6) . In addition, a case of 3TC-induced PRCA without ZDV treatment has been reported (6) . The patient in that case was a 29-year-old HIV-infected woman under treatment with 3TC, d4T and EFV. She was admitted to the hospital with signs of acute infection (fever and high levels of inflammatory markers) and pancytopenia with severe microcytic anemia. That patient was initially treated with antibiotics for possible urosepsis. After antibiotic treatment, the other blood cell counts returned to the normal ranges; however, the reduced red blood cell count persisted, and the authors switched the patient from 3TC to tenofovir (TDF). Shortly after 3TC discontinuation (one week), the patient's Hb level markedly improved. In contrast with that observed in our case, marked hypocellularity had been noted in that case following a bone marrow examination performed on admission (6) . The authors also documented the presence of patchy cellular areas, including granulopoiesis and adequate megakaryocytes, neither of which were detected in the present case. We speculate that the granulopoietic and megakaryocytic areas identified in the previous case were due to the patient's concomitant infection, as we did not observe marked hypocellularity or granulopoietic/megakaryopoietic areas in the bone marrow specimen obtained from our patient, who lacked any signs of acute infection. Consistent with other reports, the CD4 + T cell count and HIV load did not appear to affect the development of anemia in our case. In addition, autoimmune hemolysis, which can be caused by immune dysregulation in AIDS patients, was not observed in our patient, as demonstrated by the negative direct Coombs test and lack of an elevated haptoglobin level. Moreover, no red blood cell fragments were detected in the initial blood smears. Therefore, we excluded hemolysis as a possible contributing factor to the patient's anemia. Furthermore, the results of druglymphocyte stimulation tests against 3TC were negative. These findings indicate that 3TC exclusively damaged the erythrocyte formation system, thus resulting in PRCA.
In the present case, we used d4T as a substitute for 3TC instead of other NRTI alternatives, such as TDF and ZDV. TDF has been reported to cause renal proximal tubular dysfunction and decrease the glomerular filtration rate (11) . In a recent report, Japanese patients with a small body weight (<59 kg) were shown to have an increased risk of renal insufficiency (12) . In our case, given the patient's small body weight (47.2 kg), TDF may have induced drug-associated renal dysfunction. We did not select ZDV because it has been reported to induce anemia (3, 6, 10) . In contrast to the risks associated with TDF and ZDV, we believed that d4T would not cause frequent serious side effects during the short duration of use in this case.
PRCA has been reported to be associated with a variety of clinical disorders, and various autoimmune mechanisms have been described to induce red blood cell formation (13, 14) . Primary PRCA has been suggested to occur in response to both humoral and cellular immunity (15) . Some PRCA cases have been documented to be associated with CD4 + T cell activation and a high CD4/CD8 ratio, and the existence of erythropoiesis-inhibiting T cells in the bone marrow has also been reported (13) (14) (15) . In the present case, the patient's peripheral blood CD4 + and CD8 + T cell counts and CD4/CD8 ratio were within the normal limits. Furthermore, we detected neither T cell proliferation in the bone marrow nor an elevated blood CD4/CD8 ratio; however, other clinical cases of PRCA in HIV patients have been reported in the absence of obvious T cell activation (5, 16) . These facts suggest that PRCA can occur in HIV patients, who are expected to exhibit impaired T cell-mediated immunity.
In conclusion, we herein reported a case of PRCA induced by 3TC administration. We therefore warn physicians to recognize this rare adverse effect of 3TC, regardless of the presence or absence of a history of ZDV treatment.
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